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We	analyzed	1,093	Vibrio cholerae isolates from the Demo-
cratic	Republic	of	the	Congo	during	1997–2012	and	found	
increasing antimicrobial drug resistance over time. Our 
study also demonstrated that the 2011–2012 epidemic was 
caused	by	 an	El	Tor	 variant	 clonal	 complex	with	 a	 single	
antimicrobial	drug	susceptibility	profile.
Cholera is an acute intestinal infection caused by Vibrio cholerae (1). Although hydration remains the primary 
treatment for cholera, antimicrobial drug therapy is recom-
mended for severely ill patients (2). However, multidrug-
resistant V. cholerae strains have long been observed in Af-
rica (3), and strains exhibiting new resistance phenotypes 
have emerged during recent epidemics (4). It is therefore 
critical to carefully monitor changes in strains’ susceptibil-
ity to antimicrobial drugs in each African country and adapt 
treatment recommendations accordingly.
Few longitudinal studies assessing shifts in the resis-
tance of V. cholerae to antimicrobial drugs in Africa have 
been established. The available studies are limited either to 
a restricted area (5) or a short time period (6). We describe 
the long-term evolution of antimicrobial drug susceptibil-
ity of an extensive set of V. cholerae isolates collected in 
the Democratic Republic of the Congo (DRC). We applied 
whole-genome sequencing and multiple locus variable-
number tandem-repeat analysis (MLVA) to clarify the 
mechanisms behind the aggressive epidemic of 2011–2012 
that spread throughout the country, affecting regions to 
which cholera was not endemic (7).
The Study
Sample collection included all available isolates from ma-
jor outbreaks in the DRC during 1997–2012, which were 
stored at the National Institute of Biomedical Research. 
The Table shows the locations where the 1,093 tested iso-
lates were collected.
V. cholerae O1 strains stored in nutrient agar during 
1997–2012 were cultured on thiosulfate citrate bile salts 
agar and nutrient agar at the National Laboratory, Kinsha-
sa, DRC. The strains were enriched in alkaline peptone wa-
ter liquid medium and incubated at 37°C for 18–24 h. Bio-
chemical and serogroup characterization was subsequently 
performed according to standard protocols (8).
Antimicrobial drug susceptibility testing of 1,093 
confirmed V. cholerae isolates was performed by using 
the Kirby-Bauer disk diffusion method (9) with Mueller 
agar (bioMérieux, Marcy l’Etoile, France). V. cholerae 
O1 Ogawa and Inaba reference strains (ATCC) served as 
controls. Isolates were tested against 9 antimicrobial drugs 
as follows: ampicillin (10 µg), chloramphenicol (30 µg), 
sulfamethoxazole/trimethoprim (1.25 + 23.75 µg), tetra-
cycline (30 µg), doxycycline (30 µg), norfloxacin (5 µg), 
ciprofloxacin (5 µg), nalidixic acid (30 µg), and erythro-
mycin (30 µg) (bioMérieux). Interpretation of inhibition 
diameters (sensitive, intermediate, and resistant) was per-
formed according to Clinical and Laboratory Standards In-
stitute guidelines (10). When no interpretive criteria for V. 
cholerae were available from these guidelines, breakpoints 
for Enterobacteriaceae were applied by using Escherichia 
coli ATCC 25922 for quality control. The few intermedi-
ate results were categorized as resistant for this study. The 
strains were then regrouped into 21 resistance profiles. 
Seventy-four clinical isolates from the 2011–2012 
epidemic, spatiotemporally representative of outbreak 
diffusion, were subcultured and transported to Marseille, 
France. In Marseille, the strains were recultivated and iden-
tified as previously described (11). For DNA extraction, a 
50-colony aliquot of cultured cells was suspended in 500 
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µL NucliSENS easyMAG lysis buffer (bioMérieux). DNA 
was extracted by using a NucliSENS easyMAG platform 
(bioMérieux) according to the manufacturer’s instructions. 
MLVA-based genotyping of the V. cholerae isolates and 
eBURST analysis (http://eBURST.mlst.net) were per-
formed as previously described (11). To perform a phylo-
genetic assessment of the core V. cholerae genome on the 
basis of genome-wide single nucleotide polymorphisms, 
whole-genome sequencing was performed on an isolate 
(L286) collected at epidemic onset by using a HiSeq Il-
lumina System (Illumina, San Diego, CA, USA) as previ-
ously described (12).
A spatiotemporal analysis was performed on the ba-
sis of the antibiogram profiles of V. cholerae isolates col-
lected in the DRC during 1997–2012. The strain profiles 
were plotted by year (Figure 1) and then mapped by year 
and province. Using these data, we regrouped them into 5 
representative periods (Figure 2). The V. cholerae strains 
displayed an increasingly complex resistance phenotype 
to various antimicrobial drugs. Sulfamethoxazole/trim-
ethoprim resistance was observed initially, followed by 
resistance to nalidixic acid, erythromycin, and chloram-
phenicol during the early 2000s. Although sensitivity to 
fluoroquinolones seemed to be preserved, strain resistance 
patterns continued to evolve with the circulation of isolates 
resistant to tetracyclines and ampicillin from 2007–2010. 
Finally, isolates collected during 2011–2012, which was 
marked by the westward spread of a major epidemic (7), 
displayed a single antimicrobial drug susceptibility pro-
file: resistance to most antimicrobial drugs except cyclines 
and fluoroquinolones.
Serotype analysis of the 1,093 V. cholerae isolates 
showed that Inaba strains were restricted to the western re-
gion of the country, Ogawa strains were isolated in the east 
and south, and Hikojima strains were restricted to Oriental 
Province, in the northeastern region of the country. During 
2001–2010, Inaba and Ogawa serotypes were observed, but 
Ogawa predominated; during 2011–2012, these serotypes 
switched, and the Ogawa serotype was almost completely 
replaced by Inaba.
To examine the particular 2011–2012 epidemic that 
spread throughout the DRC (7), 74 V. cholerae isolates 
were assessed by using MLVA and eBURST analysis. 
Overall, the isolates displayed 19 different MLVA geno-
types, of which 18 grouped into 1 clonal complex. eBURST 
analysis indicated that the clonal complex likely arose from 
a founder strain identified at the beginning of the epidemic. 
Furthermore, whole-genome sequence analysis of an iso-
late identified in March 2011 in Lubunga, Oriental Prov-
ince (L286), revealed that the strain was an El Tor variant 
with CTX-3 type phage and a RS1 satellite phage. Phy-
logeny analysis situated this DRC strain close to the major 
Kenyan clade in the most recent wave of the seventh pan-
demic (data not shown).
Conclusions
Analysis of a panel of V. cholerae clinical isolates from 
the DRC from 1997–2012 highlighted a loss of sensitiv-
ity to leading antimicrobial drugs, although strains remain 
susceptible to fluoroquinolones. However, a risk for emer-
gence and spread of fluoroquinolone-resistant strains ex-
ists, as has been shown elsewhere in Africa (13). Because 
resistance to nalidixic acid is frequently associated with 
decreased susceptibility to fluoroquinolones, nalidixic acid 
resistance must be detected to monitor the emergence of 
highly resistant strains (14).
Our findings also provide new insight regarding the 
cholera epidemic of 2011–2012. This epidemic appears 
to have been caused by the expansion of a specific V. 
cholerae subpopulation, which rapidly diffused country-
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Table. Distribution of 1,093	Vibrio cholerae isolates, by year and province,	Democratic Republic of the Congo,	1997–2012 
Year 
Province,	no.	isolates 
Total Bandundu 
Bas-
Congo Equateur 
Kasai-
Oriental Katanga Kinshasa Maniema 
North	
Kivu Oriental 
South 
Kivu 
1997 0 4 0 0 0 2 0 0 0 0 6 
1998 0 2 0 0 15 14 0 4 7 0 42 
1999 8 0 0 0 1 22 0 0 0 0 31 
2000 3 0 10 0 0 13 0 0 0 0 26 
2001 0 0 0 0 16 0 0 0 0 0 16 
2002 0 0 0 0 44 0 0 0 0 0 44 
2003 0 0 0 19 21 4 0 0 0 0 44 
2004 0 0 0 0 1 2 0 3 0 0 6 
2005 0 0 0 0 1 0 0 2 0 0 3 
2006 2 3 0 0 9 0 0 0 0 0 14 
2007 0 0 0 0 15 1 0 1 5 0 22 
2008 0 0 0 0 30 0 5 4 17 0 56 
2009 0 0 0 0 112 0 0 2 0 11 125 
2010 0 0 0 0 10 0 0 0 0 5 15 
2011 46 0 17 0 0 73 4 151 45 0 336 
2012 11 25 16 0 1 27 0 196 31 0 307 
Total 70 34 43 19 276 158 9 363 105 16 1,093 
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wide. Furthermore, sequence analysis showed that the 
clone responsible for this epidemic, an El Tor variant 
with CTX-3 type phage, falls close to the major Kenyan 
clade in wave 3 of the seventh pandemic. This observa-
tion correlates with a 2011 study demonstrating that the 
seventh cholera pandemic had been caused by specific 
strains originating from a unique ancestral clone that have 
spread globally in successive waves (12). The 2011–2012 
isolates displayed a specific antimicrobial drug resis-
tance pattern, characterized by the return of tetracycline 
and doxycycline sensitivity. The outbreak strain also 
represented a serotype switch from Ogawa to Inaba. 
However, further MLVA genotyping of preoutbreak iso-
lates is required to determine whether these strains were 
already present in the region or if they represent a new 
V. cholerae population.
This study demonstrates that molecular and micro-
biological analyses of V. cholerae isolates provide exten-
sive insight into the mechanisms of cholera epidemics. 
MLVA and whole-genome sequencing are powerful tools 
for elucidating epidemic dynamics because these methods 
have been used to link distinct outbreaks and identify the 
origin of certain epidemic V. cholerae strains (15). Im-
proved sampling of clinical isolates is essential to moni-
tor changes in pathogen antimicrobial drug resistance and 
elucidate the dissemination pathways of toxigenic strains 
to ensure proper management of patients requiring anti-
microbial drug treatment and to appropriately direct the 
public health response.
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Figure 1. Vibrio cholerae	strain	antimicrobial	drug	resistance	profiles	plotted	by	year,	Democratic	Republic	of	the	Congo,	1997–2012.	
On	the	basis	of	the	antibiogram	results,	strains	were	grouped	into	21	antimicrobial	drug	resistance	profiles.	The	antimicrobial	drugs	to	
which the strains displayed resistance are indicated on the right. Circle circumference represents the relative number of isolates per 
profile.	AM,	ampicillin;	C,	chloramphenicol;	SXT,	sulfamethoxazole/trimethoprim;	TE,	tetracycline;	DO,	doxycycline;	NOR,	norfloxacin;	CI,	
ciprofloxacin;	NA,	nalidixic	acid;	E,	erythromycin.
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